stars 1 stars 2 stars 3

EdiGene is a clinical-stage company focused on translating gene-editing technologies into transformative genetic medicines for patients with significant unmet medical needs. Anchored by its proprietary technologies of gene editing, bioinformatics, and high throughput genome-editing screening, EdiGene advances the pipeline on therapeutic platforms of LEAPER-based in vivo RNA base editing, ex vivo gene-editing hematopoietic stem cells, and ex vivo gene-editing T cells for allogeneic CAR-T.

EdiGene Inc. Questions

The EdiGene Inc. annual revenue was $29.6 million in 2026.

Zhang W is the Senior Director of Pre-clinical Evaluation of EdiGene Inc..

23 people are employed at EdiGene Inc..

EdiGene Inc. is based in Changping District, Beijing.

The NAICS codes for EdiGene Inc. are [541, 54, 62151, 621, 3254, 32, 6215, 325, 325413, 32541, 62].

The SIC codes for EdiGene Inc. are [28, 87, 873].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users